186 related articles for article (PubMed ID: 12610499)
1. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W
Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
[TBL] [Abstract][Full Text] [Related]
6. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
8. GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
Vaughan MM; Moore J; Riches PG; Johnston SR; A'Hern RP; Hill ME; Eisen T; Ayliffe MJ; Thomas JM; Gore ME
Ann Oncol; 2000 Sep; 11(9):1183-9. PubMed ID: 11061616
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Lewis KD; Gibbs P; O'Day S; Richards J; Weber J; Anderson C; Zeng C; Baron A; Russ P; Gonzalez R
Cancer Invest; 2005; 23(4):303-8. PubMed ID: 16100942
[TBL] [Abstract][Full Text] [Related]
11. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
12. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
13. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
[TBL] [Abstract][Full Text] [Related]
14. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Ridolfi R; Romanini A; Sileni VC; Michiara M; Guida M; Biasco G; Poletti P; Amaducci L; Leoni M; Ravaioli A
Melanoma Res; 2004 Aug; 14(4):295-9. PubMed ID: 15305161
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Minor DR; Madland MT; Kashani-Sabet M; Denny SR; Harvey WB
Cancer Biother Radiopharm; 2005 Oct; 20(5):479-86. PubMed ID: 16248763
[TBL] [Abstract][Full Text] [Related]
19. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Weber RW; O'Day S; Rose M; Deck R; Ames P; Good J; Meyer J; Allen R; Trautvetter S; Timmerman M; Cruickshank S; Cook M; Gonzalez R; Spitler LE
J Clin Oncol; 2005 Dec; 23(35):8992-9000. PubMed ID: 16260693
[TBL] [Abstract][Full Text] [Related]
20. Biochemotherapy in the treatment of metastatic melanoma in selected patients.
González Astorga B; Jiménez Rubiano B; Delgado Pérez JR; Valdivia Bautista J; Sánchez Toro C; González Flores E; Luque Caro R; Castellón Rubio V
Clin Transl Oncol; 2009 Jun; 11(6):382-6. PubMed ID: 19531453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
